part 3: obstacles to developing targeted cancer...
TRANSCRIPT
![Page 1: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/1.jpg)
Part 3: Obstacles to Developing Targeted
Cancer Therapies
Adrianna San RomanLeah Liu
Clare Malone
![Page 2: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/2.jpg)
If targeted therapies are so great, why can’t we
treat all cancers?
![Page 3: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/3.jpg)
Obstacles
• Identifying targets
• Finding medicines for targets
• Moving into the clinic
• Cancer resistance
![Page 4: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/4.jpg)
Obstacle 1: Targeted therapies require targets!
Wikimedia
![Page 5: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/5.jpg)
How do you identify a target?
Discover differences between normal cells and cancer cells:
• DNA mutations
• Protein levelsProblem: Most cancer cells have DNA that looks like someone exploded their
DNA and then put it back together randomlyMichale Strock
![Page 6: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/6.jpg)
Driver vs. Passenger Mutations
“Driver” is causing the cancer
“Passenger” is a mutation that happens along the way to becoming cancer, but isn’t causing the cancer
![Page 7: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/7.jpg)
Which mutations are “drivers”?
geograph.org.uk
![Page 8: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/8.jpg)
Solution: Look for common mutations in many tumor
samples
However, rare but important “driver” mutations will be overlooked, and are very
difficult to identify
Sample 1 Sample 2 Sample 3 Sample 4
![Page 9: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/9.jpg)
Not all driver mutations are good targets
B DCA
Normal Cancer
![Page 10: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/10.jpg)
Obstacle 2: Hitting the Target
![Page 11: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/11.jpg)
Which protein has a targeted therapy?
Mutated in 20-25% of all human cancers
Importance in human cancer discovered in
1982
Mutated in 7% of all human cancers
Importance in human cancer discovered in
2002
✔
A
B B-raf
Ras
![Page 12: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/12.jpg)
Cell Growth Example – Ras Pathway
B-raf
Abnormal cell growth
and division
Ras Mek
Cancer Cell
Signal
Receptor
Pathway Compone
nt
Pathway Compone
nt
Output
Pathway Compone
nt
PLX4032Growth signal Cell
growth and
division
![Page 13: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/13.jpg)
p53
Tumor suppressors: How do you “target” something that is
not there?
Fixing mistakes in DNA
Control of Cell Division
Control of Cell Death
![Page 14: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/14.jpg)
So far we’ve learned…
1. It can take years of research to identify promising targets
2. It can be difficult or impossible to find medicines that alter promising targets
![Page 15: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/15.jpg)
Obstacle 3: Moving from the lab to the clinic does not
always workClick to edit Master text styles
Second level● Third level
● Fourth level● Fifth level
Photo by Umberto Salvagnin http://www.flickr.com/photos/kaibara/3075268200/
![Page 16: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/16.jpg)
How many potential medicines make it into
clinical trials?
A.) 1 in 100
B.) 1 in 1000
C.) 1 in 10,000
![Page 17: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/17.jpg)
Why don’t they make it to clinical trial?
• Cannot be effectively delivered to patient (oral, IV etc)
• Not stable enough for use in the clinic
• Not specific for target
• Toxic to normal cells
![Page 18: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/18.jpg)
Most potential medicines fail in clinical trials
All indications Breast Cancer Colorectal Cancer0
102030405060708090
100
Med
icin
es a
pp
roved
aft
er
tria
ls
7% 4% 3% 2%9% 8%
BioMedTracker BIO study 2011Insidebiola.com
![Page 19: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/19.jpg)
Why do medicines fail?
• Can’t give enough medicine to people
• Medicine does not do what we thought it would
• Medicine hits target, but target is less important than we thought
2.) Medicine has too many side effects
1.) Medicine is not effective
• “Off-target” effects• Hitting target not safe
Therapeutic window
Dose
Benefit
![Page 20: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/20.jpg)
Targeted therapies might have better luck
• More is understood about the biology before trials are started (better efficacy)
PLX4032’s end-stage clinical trial is the shortest on record!
B-raf
Cancer growth
• Risk of serious side-effects is expected to be lower (safer)
This means a wider therapeutic window, so it is easier to achieve effective doses safely!
![Page 21: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/21.jpg)
Obstacle 4: Cancer is always changing
![Page 22: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/22.jpg)
How does cancer fight back?
Medicine Resistance
![Page 23: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/23.jpg)
Resistance to PLX4032
Before therapy After therapy Average relapse: 7 months
?
Flaherty et al. N Engl J Med 2010; 363:809-819.
![Page 24: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/24.jpg)
Mechanism of Resistance #1
Cancer cell growth and
division
Cancer cell growth and
division
New mutation
Secondary mutation in the target protein
![Page 25: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/25.jpg)
Ras Pathway
B-rafRas
Growth signal
Mek
Cell
Signal
Receptor
Pathway Compone
nt
Pathway Compone
nt
Output
Pathway Compone
nt
Cell growth
and division
![Page 26: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/26.jpg)
Mechanism of Resistance #2
Cancer cell growth and
division
B-raf
Mek
Mutation in a downstream protein
![Page 27: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/27.jpg)
Mechanism of Resistance #3
Cancer cell growth and
division
B-raf
Mek
Mutation bypasses target protein
![Page 28: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/28.jpg)
Cancer resistance to targeted therapies
• Resistance is a common problem in targeted therapies
• Some common mechanisms include:² Second mutation in the target protein² Mutation in a protein downstream of the target² Mutation that bypasses the target protein
• Combination therapies may help combat resistance
![Page 29: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/29.jpg)
What we learned tonight:
Adrianna: Principles of cancer• How cancer cells are different from normal
cells• Why is not one disease
Leah: Cancer therapeutics• Chemotherapy and radiation • Targeted therapies
Clare: Obstacles to developing cancer therapies• Identifying and hitting targets• Translating discoveries to the clinic• Cancer resistance to therapy
![Page 30: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/30.jpg)
Why haven’t we won the war on cancer yet?
Because it is not one war, so it requires more than one solution.
![Page 31: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/31.jpg)
We have made progress in some major battles!
Cancer Type 1975 5-year Survival Rate 2011 5-year Survival Rate
Promyelocytic Leukemia 35% 98%
Childhood Leukemias 30% 80%
Chronic Myelogenous Leukemia
23.1% 89%
Fausel, 2007 Druker NEJM 2006SEER Cancer Statistics Review. 1975-2008
![Page 32: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/32.jpg)
What does the future of cancer therapy look like?
Near Future:• More targeted therapies
• Second- and third-line therapies to combat resistance
Distant Future:• Combination of medicine specific for patient
• Manageable chronic disease
![Page 33: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/33.jpg)
Thank you!SITN would like to acknowledge the following organizations for
their generous support.
Harvard Medical SchoolOffice of Communications and External Relations
Division of Medical Sciences
The Harvard Graduate School of Arts and Sciences (GSAS)
The Harvard Graduate Student Council (GSC)
The Harvard Biomedical Graduate Students Organization (BGSO)
The Harvard/MIT COOP
Restaurant Associates
![Page 34: Part 3: Obstacles to Developing Targeted Cancer Therapiessitn.hms.harvard.edu/wp-content/uploads/2011/05/cancer-31.pdf · Targeted therapies might have better luck • More is understood](https://reader034.vdocuments.net/reader034/viewer/2022050518/5fa199c5ac34143b452ee034/html5/thumbnails/34.jpg)
Questions?